MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rec.2022.02.001

Медицинская библиотека · Revista espanola de cardiologia (English ed.) · 2022

Temporal trend and potential impact of angiotensin receptor neprilysin inhibitors on transcatheter edge-to-edge mitral valve repair.

Barrero Alejandro, Carrasco-Chinchilla Fernando, Benito-González Tomás, Pascual Isaac, Arzamendi Dabit, Estévez-Loureiro Rodrigo, Nombela-Franco Luis, Pan Manuel, Freixa Xavier, Trillo-Nouche Ramiro, Sánchez-Recalde Ángel, Andraka Leire, Cruz-González Ignacio, López-Mínguez José Ramón, Diez Gil José Luis, Urbano-Carrillo Cristóbal, Sanmiguel Cervera Darío, Sanchis Juan, Bosa Francisco, Ruiz Valeriano, Del Trigo María, Molina Eduardo, Serrador Ana M, Alonso-Briales Juan H, Garrote Carmen, Avanzas Pablo, Li Chi Hion, Baz José Antonio, Jiménez-Quevedo Pilar, Mesa Dolores, Regueiro Ander, Cid Belén, Carrasco-Moraleja Manuel, Rodríguez-Gabella Tania, Hernández-García José M, Fernández-Vázquez Felipe, Amat-Santos Ignacio J, Spanish TEER Group

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION AND

OBJECTIVES

Transcatheter edge-to-edge repair (TEER) should be considered in patients with heart failure and secondary mitral regurgitation (MR). Angiotensin receptor-neprilysin inhibitors (ARNIs) have been demonstrated to improve prognosis in heart failure. We aimed to evaluate the impact ARNIs on patient selection and outcomes.

METHODS

The population of the Spanish TEER prospective registry (March 2012 to January 2021) was divided into 2 groups: a) TEER before the ARNI era (n=450) and b) TEER after the recommendation of ARNIs by European Guidelines (n=639), with further analysis according to intake (n=52) or not (n=587) of ARNIs.

RESULTS

A total of 1089 consecutive patients underwent TEER for secondary MR. In the ARNI era, there was a reduction in left ventricle dilation (82mL vs 100mL, P=.025), and better function (35% vs 38%, P=.011). At 2 years of follow-up, mortality (10.6% vs 17.3%, P <.001) and heart failure readmissions (16.6% vs 27.8%, P <.001) were lower in the ARNI era, but not recurrent MR. In the ARNI era, 1- and 2-year mortality were similar irrespective of ARNI intake but patients on ARNIs had a lower risk of readmission+mortality at 2 years (OR, 0.369; 95%CI, 0.137-0.992; P=.048), better NYHA class, and lower recurrence of MR III-IV (1.9% vs 14.3%, P=.011).

CONCLUSIONS

Better patient selection for TEER has been achieved in the last few years with a parallel improvement in outcomes. The use of ARNIs was associated with a significant reduction in overall events, better NYHA class, and lower MR recurrence.

Для цитирования: Barrero Alejandro, Carrasco-Chinchilla Fernando, Benito-González Tomás, Pascual Isaac, Arzamendi Dabit, Estévez-Loureiro Rodrigo, Nombela-Franco Luis, Pan Manuel, Freixa Xavier, Trillo-Nouche Ramiro, Sánchez-Recalde Ángel, Andraka Leire, Cruz-González Ignacio, López-Mínguez José Ramón, Diez Gil José Luis, Urbano-Carrillo Cristóbal, Sanmiguel Cervera Darío, Sanchis Juan, Bosa Francisco, Ruiz Valeriano, Del Trigo María, Molina Eduardo, Serrador Ana M, Alonso-Briales Juan H, Garrote Carmen, Avanzas Pablo, Li Chi Hion, Baz José Antonio, Jiménez-Quevedo Pilar, Mesa Dolores, Regueiro Ander, Cid Belén, Carrasco-Moraleja Manuel, Rodríguez-Gabella Tania, Hernández-García José M, Fernández-Vázquez Felipe, Amat-Santos Ignacio J, Spanish TEER Group. Temporal trend and potential impact of angiotensin receptor neprilysin inhibitors on transcatheter edge-to-edge mitral valve repair.. Revista espanola de cardiologia (English ed.). 2022. DOI: 10.1016/j.rec.2022.02.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.